Last reviewed · How we verify
fluticasone propionate/salmeterol combination DISKUS
Fluticasone propionate (an inhaled corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.
Fluticasone propionate (an inhaled corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | fluticasone propionate/salmeterol combination DISKUS |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and sustained airway opening. Together, they provide both anti-inflammatory and bronchodilator effects for maintenance asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Oral candidiasis
- Throat irritation
Key clinical trials
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus® (PHASE3)
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (PHASE3)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler (NA)
- Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs (PHASE1)
- MGR001 / Advair Diskus Local Equivalence Study in Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: